Advertisement

Drugs & Therapy Perspectives

, Volume 5, Issue 6, pp 11–14 | Cite as

Leishmaniasis: pentavalent antimonials still primary therapy

New Drugs and Therapeutics

Keywords

Allopurinol Visceral Leishmaniasis Leishmaniasis Pentamidine Cutaneous Leishmaniasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Koff AB, Rosen T. Treatment of mucocutaneous leishmaniasis. J Am Acad Dermatol 1994; 31 (5 Pt 1): 693–708PubMedCrossRefGoogle Scholar
  2. 2.
    Bhadra R. Antileishmanial agents. Drug Fut 1993; 18: 451–63Google Scholar
  3. 3.
    Ho JL, Hatzigeorgiou D, Reed SG, et al. Cytokines in the treatment of leishmaniasis: from studies of immunopathology to patient therapy. Biotherapy 1994; 7: 223–35PubMedCrossRefGoogle Scholar
  4. 4.
    Martindale. The Extra Pharmacopoeia, 30th ed. London; The Pharmaceutical Press, 1993; 509–27Google Scholar
  5. 5.
    Lockwood DNJ, Pas vol G. Recent advances in tropical medicine. BMJ 1994; 308: 1559–62PubMedCrossRefGoogle Scholar
  6. 6.
    Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med 1992; 46: 296–306Google Scholar
  7. 7.
    Jernigan JA, Pearson RD. Chemotherapy of leishmaniasis, Chagas’ disease and African trypanosomiasis. Curr Opin Infect Dis 1993; 6: 794–802CrossRefGoogle Scholar
  8. 8.
    Cook GC. Leishmaniasis: some recent developments in chemotherapy. J Antimicrob Chemother 1993; 31: 327–30PubMedCrossRefGoogle Scholar
  9. 9.
    Soto-Mancipe J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 1993; 16: 417–25PubMedCrossRefGoogle Scholar
  10. 10.
    Mishra M, Biswas UK, Jha AM, et al. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet 1994; 344: 1599–600PubMedCrossRefGoogle Scholar
  11. 11.
    Mishra M, Biswas UK, Jha AM, et al. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet 1992; 340: 1256–7PubMedCrossRefGoogle Scholar
  12. 12.
    Targeting drugs using liposomes: new drugs from old. Drug Ther Perspect 1993 Mar 8; 1(4): 13–15Google Scholar
  13. 13.
    Dietze R, Milan EP, Berman JD, et al. Treatment of Brazilian kala-azar with a short course of Amphocil (amphotericin B cholesterol dispersion). Clin Infect Dis 1993; 17: 981–6PubMedCrossRefGoogle Scholar
  14. 14.
    Davidson RN, Di Martino L, Gradoni L, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 1994; 87: 75–81PubMedGoogle Scholar
  15. 15.
    Wali JP, Aggarwal P, Gupta U, et al. Ketoconazole in the treatment of antimony-and pentamidine-resistant kala-azar [letter]. J Infect Dis 1992; 166: 215–6PubMedCrossRefGoogle Scholar
  16. 16.
    Wali JP, Aggarwal P, Gupta U, et al. Ketoconazole in the treatment of visceral leishmaniasis [letter]. Lancet 1990; 336: 810–1PubMedCrossRefGoogle Scholar
  17. 17.
    Sundar S, Kumar K, Singh VP. Ketoconazole in visceral leishmaniasis [letter]. Lancet 1990; 336: 1582–3PubMedCrossRefGoogle Scholar
  18. 18.
    Navin TR, Arana BA, Arana FE, et al. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165: 528–34PubMedCrossRefGoogle Scholar
  19. 19.
    Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med 1990; 89: 147–55PubMedCrossRefGoogle Scholar
  20. 20.
    Akuffo H, Dietz M, Teklemariam S, et al. The use of itraconazole in the treatment of leishmaniasis caused by Leishmania aethiopica. Trans R Soc Trop Med Hyg 1990; 84: 532–4PubMedCrossRefGoogle Scholar
  21. 21.
    Al-Fouzan AS, Al Saleh QA, Narem NM, et al. Cutaneous leishmaniasis in Kuwait. Int J Dermatol 1991; 30: 519–21PubMedCrossRefGoogle Scholar
  22. 22.
    Dogra J, Aneja N, Behari B, et al. Cutaneous leishmaniasis in India. Int J Dermatol 1990; 29: 661–2PubMedCrossRefGoogle Scholar
  23. 23.
    Day RO, Birkett DJ, Hicks M, et al. New uses for allopurinol. Drugs 1994; 48: 339–44PubMedCrossRefGoogle Scholar
  24. 24.
    Martinez S, Marr JJ. Allopurinol in the treatment of american cutaneous leishmaniasis. N Engl J Med 1992; 326: 741–4PubMedCrossRefGoogle Scholar
  25. 25.
    Saenz RE, Paz HM, Johnson CM, et al. Treatment of American cutaneous leishmaniasis with orally administered allopurinol riboside. J Infect Dis 1989; 160: 153–8PubMedCrossRefGoogle Scholar
  26. 26.
    Ragusa R, Di Cataldo A, Samperi P, et al. Treatment of visceral leishmaniasis with meglumine and allopurinol [letter]. Am J Dis Child 1993; 147: 611–2PubMedGoogle Scholar
  27. 27.
    di Martino L, Pettoello Mantovani M, Gradoni L, et al. Low dosage combination of meglumine antimoniate plus allopurinol as first choice treatment of infantile visceral leishmaniasis in Italy. Trans R Soc Trop Med Hyg 1990; 84: 534–5PubMedCrossRefGoogle Scholar
  28. 28.
    Laguna F, Lopez-Vélez R, Soriano V, et al. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV. J Infect 1994; 28: 255–9PubMedCrossRefGoogle Scholar
  29. 29.
    Playfair JHL, Blackwell JM, Miller HRP. Parasitic diseases. Lancet 1990; 335: 1263–6PubMedCrossRefGoogle Scholar
  30. 30.
    Convit J, Rondon A, Ulrich M, et al. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet 1987 Feb 21; 1: 401–4PubMedCrossRefGoogle Scholar
  31. 31.
    Nascimento E, Mayrink W, Dacosta CA, et al. Vaccination of humans against cutaneous leishmaniasis: cellular and humoral responses. Infect Immun 1990; 58: 2198–2203PubMedGoogle Scholar

Copyright information

© Adis International Limited 1995

Personalised recommendations